← LeaderboardsInvestigatorsiAttributed = a PI's even-split share of each grant — a $1M grant with 2 PIs counts $500K each.
Global Alliance For Tb Drug Development
New York, NY
$35,762,738
Total funding
12
Grants
Funding over time
peak $12.1M · FY2010–24$20M$15M$10M$5M$0
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
Funding mix
By agency
NIH$33,160,145 · 10
FDA$2,602,593 · 2
By mechanism
U19$28,468,137 · 8
U18$2,602,593 · 2
N01$2,475,623 · 1
R24$2,216,385 · 1
Investigators at Global Alliance For Tb Drug Development
InvestigatorsiAttributed = a PI's even-split share of each grant — a $1M grant with 2 PIs counts $500K each.
Exposure= the full size of every grant they're on ($1M each).
Rising Stars
First grant in the last 5 yrs
Not enough data
Emerging Leaders
6–10 yrs in
Not enough data
All-Time
Most funded here, all years
Largest grants
Modulation of Protein production and Degradation as an integrated approach to rapid sterilization of Drug sensitive and resistant Mtb.$6,025,401
U19 · FY2021 · AI
Modulation of Protein production and Degradation as an integrated approach to rapid sterilization of Drug sensitive and resistant Mtb.$5,956,416
U19 · FY2022 · AI
Modulation of Protein production and Degradation as an integrated approach to rapid sterilization of Drug sensitive and resistant Mtb.$5,528,394
U19 · FY2020 · AI
Modulation of Protein production and Degradation as an integrated approach to rapid sterilization of Drug sensitive and resistant Mtb.$5,485,460
U19 · FY2019 · AI
Modulation of Protein production and Degradation as an integrated approach to rapid sterilization of Drug sensitive and resistant Mtb.$5,472,466
U19 · FY2023 · AI
Scientific Core - Compound Optimization and Prioritization.$2,822,282
U19 · FY2023 · AI
Scientific Core - Compound Optimization and Prioritization.$2,652,211
U19 · FY2021 · AI
Development of Therapeutic Candidates for Biodefense, Antimicrobial Resistant (AMR) Infections and Emerging Infectious Diseases$2,475,623
N01 · FY2024 · AI
Scientific Core - Compound Optimization and Prioritization.$2,128,141
U19 · FY2020 · AI
Scientific Core - Compound Optimization and Prioritization.$2,043,428
U19 · FY2019 · AI
UIC: In vitro In vivo Mtb Pharmacology$1,066,689
U19 · FY2021 · AI
UIC: In vitro In vivo Mtb Pharmacology$1,012,839
U19 · FY2019 · AI
UIC: In vitro In vivo Mtb Pharmacology$1,007,216
U19 · FY2020 · AI
Project 1 UIC Targeting Protein Degradation ClpC1 ATPase$980,256
U19 · FY2020 · AI
UIC: In vitro In vivo Mtb Pharmacology$963,450
U19 · FY2023 · AI
Project 1 UIC Targeting Protein Degradation ClpC1 ATPase$953,949
U19 · FY2021 · AI
Project 1 UIC Targeting Protein Degradation ClpC1 ATPase$851,030
U19 · FY2019 · AI
Discovery of inhibitors that target the Mtb ClpP1P2 protease$850,917
U19 · FY2022 · AI
Scientific Core - Compound Optimization and Prioritization.$850,917
U19 · FY2022 · AI
UIC: In vitro In vivo Mtb Pharmacology$850,917
U19 · FY2022 · AI